title: Soft tissue calcification secondary to imatinib mesylate in a patient with gastrointestinal stromal tumor.
abstract: Imatinib mesylate has been associated with the changes in bone turnover. We report a case of the development of tissue calcification in a patient on long-term therapy with this drug. A 48-year-old male patient with gastrointestinal stromal tumor and liver metastasis complained of abdominal pain. His treatment included hepatic artery chemoembolization and partial hepatectomy in addition to chronic imatinib mesylate for 4 years. On physical examination, he had a peritoneal mass just beneath the laparotomy incision scar that, after resection, was found to be dystrophic bone formation. Based on the previous studies suggesting bone changes due to chronic therapy with imatinib mesylate, we believe that the patient's new bone formation was causally related to the use of this drug. To our knowledge, there are no similar reported cases in the literature.
authors.affiliation: Department of Internal Medicine, Division of Hematology/Oncology, East Tennesse State University College of Medicine, Johnson City, TN, USA.
authors.forename: Robert E
authors.initials: RE
authors.lastname: Enck
authors.forename: Fadi
authors.initials: F
authors.lastname: Abushahin
authors.forename: John B
authors.initials: JB
authors.lastname: Bossaer
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D001549:Benzamides / Q000009:adverse effects* / Q000627:therapeutic use*; D002113:Calcification, Physiologic / Q000187:drug effects*; D046152:Gastrointestinal Stromal Tumors / Q000188:drug therapy*; D006801:Humans; D000068877:Imatinib Mesylate; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000009:adverse effects* / Q000627:therapeutic use*; D011743:Pyrimidines / Q000009:adverse effects* / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate
keywords: Gastrointestinal stromal tumor; imatinib mesylate; new bone formation